ライフサイエンスコーパス: MPH

1 MPH + FLX enhanced sensitivity to drug (i.e., cocaine) a

2 MPH + FLX exposure also increased mRNA of ERK2 and its d

3 MPH administration improved behavioral performance and i

4 MPH also improved reaction times to make correct respons

5 MPH elicited a more complex pattern of actions on reward

6 MPH enhanced activity within individual neurons, ensembl

7 MPH enhances catecholamine transmission via blockade of

8 MPH is also used, without license, by healthy adults, bu

9 MPH landscapes, computed for (noisy) data from agent-bas

10 MPH led to an overall suppression of alpha activity acro

11 MPH led to increased rates of target detection, and elec

12 MPH produced a broad inverted-U-shaped facilitation of s

13 MPH resulted in a statistically significant improvement

14 MPH serves to reduce maladaptive electrophysiological pr

15 MPH significantly increased thalamo-cerebellar connectiv

16 MPH treatment increased impulsivity in LI rats, and modu

17 MPH use in DCD procurements does not lead to delays in W

18 MPH's normalization of thalamo-accumbens connectivity (r

19 MPH-220 provides a potential nervous-system-independent

20 MPH-related enhancements occurred without significant ch

21 <0.001; cumulative PH: MD -0.287, P <0.001; MPH: MD -0.288, P <0.001; DPH: MD -0.310, P <0.001).

22 show that wind speeds of 4.5-6.7 m/s (10-15 MPH) reduce the average methane destruction efficiency t

23 ; age range, 10-12 years) and 48 men (n = 24 MPH group, n = 24 placebo group; age range, 23-40 years)

24 e error correction.ResultsFifty boys (n = 25 MPH group, n = 25 placebo group; age range, 10-12 years)

25 o the enzyme ([Fe(2+)]PAH(R)[L-Phe,5-deaza-6-MPH(4)]), the active site converts to a five-coordinate

26 ence+placebo and (c) 24 h smoking abstinence+MPH.

27 treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18).

28 ning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention

29 g memory and divided attention (MAAT/MPH>ABT/MPH).

30 mposed of patients who were not administered MPH (brain tumor = 31 and acute lymphoblastic leukemia =

31 disorder (CUD) twice after placebo and after MPH (0.5 mg/kg, iv).

32 ed decreased striatal D2R availability after MPH and these decreases were smaller in METH than in con

33 an in controls, and had no D2R changes after MPH challenge.

34 ermic machine perfusion of heart allografts (MPH) has led to rapid growth in transplantation of donat

35 The opposing effects of ATO and MPH in the NAcb core and shell on impulsivity were unlik

36 l mortality or fecundity between control and MPH lines.

37 ndisplaceable binding potential (BP(ND)) and MPH dose in the head of the caudate (hCd), demonstrating

38 leus accumbens was lower for the placebo and MPH measures, that MPH-induced increases in thalamic met

39 in DAT1, previously linked to ADHD risk and MPH behavioural responses, influences the neurophysiolog

40 CA and dominance-related effects for SCA and MPH, and additive-by-dominant effect for MPH was partly

41 pairments in CUD; separately, RE (trend) and MPH conditions recruited the vmPFC, and RE's vmPFC-relia

42 We then apply MPH landscapes to study immune cell location in digital

43 ant to note that EX was just as effective as MPH or ATMX in reducing orienting behavior and social in

44 BackgroundMethylphenidate (MPH) is highly effective in treating attention-deficit/h

45 ould cause transgenerational effects because MPH can affect the male germline in rodents and because

46 Before MPH treatment, we found that D2/3 receptor availability

47 Both MPH and ATX increased SICI in heterozygotes but not in 1

48 ences the neurophysiological effects of both MPH and ATX.

49 gest that elevated catecholamine activity by MPH can disrupt inhibitory influences on persistent risk

50 , we tested for modulation of this effect by MPH in 40 healthy human adults.

51 Targeting skeletal muscle myosin by MPH-220 enabled muscle relaxation, in human and model sy

52 lamus and accumbens in CUD was normalized by MPH (reducing negative connectivity).

53 sive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating th

54 [(1)(1)C]MPH and [(1)(1)C]raclopride dynamic PET scans were perfo

55 Chronic MPH did not differentially alter the course of weight ga

56 interaction between environment and chronic MPH treatment at clinically relevant doses, administered

57 ed the effects of discontinuation of chronic MPH treatment on regional cerebral blood flow (rCBF) in

58 erm neurobiological consequences of combined MPH and FLX treatment (MPH + FLX) during juvenile period

59 shed placebo controlled trials that compared MPH and placebo on executive and nonexecutive memory, re

60 In conclusion, MPH and ATX have similar effects on SICI in children wit

61 These results indicate that concurrent MPH + FLX exposure during preadolescence increases sensi

62 with a truncated single guide RNA containing MPH-recruiting MS2 aptamers, and silence endogenous gene

63 237 DCD procurements met inclusion criteria (MPH: 109 and control: 1128).

64 Crucially, MPH-combined RE normalized cortico-limbicprocessing, byp

65 treated with either 0, 2, 4, or 8 mg/kg/day MPH for 3 weeks.

66 at 3 months were associated with first-dose MPH-mediated FC reductions restricted to frontal-prefron

67 erved opposing actions of low- and high-dose MPH on the population-based representation of delay: low

68 cross-over trial of placebo (bid), low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid), and moderate-d

69 maximum dose, 10 mg bid), and moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid).

70 riatum, which is normalized following either MPH or l-dopa administration.

71 n Brain Development-Methylphenidate, or ePOD-MPH) among ADHD referral centers between October 13, 201

72 connectivity (FC) associated with the first MPH dose in boys newly diagnosed with ADHD predict MPH-a

73 inutes after the administration of the first MPH dose to 40 stimulant drug-naive boys newly diagnosed

74 and MPH, and additive-by-dominant effect for MPH was partly identified as additive effect; 2) the ran

75 No trend was observed for MPH effectiveness in improving learning of a word associ

76 patients who are more likely to benefit from MPH.

77 No significant side effects from MPH were observed.

78 Recovery from MPH treatment was also examined at 1, 5, and 10 weeks fo

79 ng increased extracellular DA resulting from MPH administration.

80 rom trait phenotype, and fewer QTL were from MPH than from other dependent variables.

81 edial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the ca

82 In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir densi

83 Here, MPH was evaluated for its potential to alter stimulus-dr

84 ng ability (SCA) and mid-parental heterosis (MPH).

85 data is multiparameter persistent homology (MPH).

86 We examined how MPH influenced known electrophysiological precursors of

87 ditor (PE), a fusion activator MS2-p65-HSF1 (MPH), and a drive-and-process multiplex array that produ

88 treated with methylphenidate hydrochloride (MPH) to evaluate genetic and behavioral toxicity were ob

89 Methylphenidate hydrochloride (MPH; e.g. Ritalin) is a dopaminergic drug that is highly

90 Although academic gains were not identified, MPH may offer benefits in academic areas not assessed.

91 alamus neuropeptide Y-ir increased by 10% in MPH-exposed rats.

92 se in FA (standardized effect size, 5.25) in MPH-treated boys.

93 ological markers in 16 regions implicated in MPH effects and/or ADHD etiology.

94 he commonly occurring brief interruptions in MPH treatment.

95 possible role of the default mode network in MPH-mediated improvements in inattention and hyperactivi

96 neither in striatal D2R availability nor in MPH-induced striatal DA changes.

97 During transient inhibition, MPH increased prefrontal activation for both groups and

98 allowed us to design a selective inhibitor, MPH-220.

99 their actions as competitive DAT inhibitors (MPH, cocaine) and substrates (AMPH).

100 core improvement was associated with initial MPH-mediated FC reductions restricted to occipitoparieta

101 A dose of 1 mg/kg intraperitoneal MPH, either single dose or chronic treatment (well withi

102 le-dose, crossover study comparing 0.5 mg/kg MPH with 1.0 mg/kg ATX in 16 children with ADHD, aged 8-

103 and [(18)F]fallypride, rats received 6 mg/kg MPH, orally, twice each day for 28 d.

104 bal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided at

105 y working memory and divided attention (MAAT/MPH>ABT/MPH).

106 , yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT

107 acebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory wor

108 lls (DCs, 440 +110/-90 Pa), and macrophages (MPHs, 900 +110/-100 Pa).

109 Our findings show that main MPH-related FC changes at rest can be understood through

110 George W. Comstock (1915-2007), MD, MPH, DrPH, was lecturer and then professor of epidemiolo

111 feature the lecture by Sharmila Dorbala, MD, MPH, a professor of radiology at the Harvard Medical Sch

112 Economy, MD, MPH; Thijs M.H. Eijsvogels, PhD; Michael S.

113 Shah, MD, MPH, FACC; Sanjay Sharma, BSc (Hons), MBChB, MRCP (UK),

114 Wasfy, MD, MPH, FACC; Matthias Wilhelm, MD.

115 Methylphenidate (MPH) ameliorates attention problems experienced by some

116 Methylphenidate (MPH) has long been used to treat attention-deficit/hyper

117 Methylphenidate (MPH) is a first line treatment for ADHD and is also misu

118 Methylphenidate (MPH) is a stimulant that increases extracellular levels

119 Methylphenidate (MPH) is an effective symptomatic treatment of attention

120 Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but it

121 Methylphenidate (MPH) is commonly diverted for recreational use, but the

122 Methylphenidate (MPH) is commonly prescribed for children who have been d

123 Methylphenidate (MPH) is used clinically to treat attention-deficit/hyper

124 Methylphenidate (MPH) normalizes cortical function, enhancing task salien

125 Methylphenidate (MPH), a commonly used dopaminergic agent, may affect ani

126 ects of orally administered methylphenidate (MPH), a first-line treatment for attention deficit hyper

127 ation of stimulants such as methylphenidate (MPH) in children with attention deficit hyperactivity di

128 Stimulants, such as methylphenidate (MPH), are beneficial for attention-deficit/hyperactivity

129 therapeutic drugs, such as methylphenidate (MPH), which also alters behavioral and cognitive functio

130 timulant medication such as methylphenidate (MPH); however, approximately 25% of patients show little

131 ined the effects of chronic methylphenidate (MPH) treatment on brain dopamine (DA) systems, developme

132 psychostimulants, including methylphenidate (MPH), are highly effective in the treatment of attention

133 Psychostimulants, including methylphenidate (MPH), improve cognitive processes dependent on the prefr

134 d DA/NE re-uptake inhibitor methylphenidate (MPH), both with proven clinical efficacy in ADHD, on the

135 ts of two ADHD medications, methylphenidate (MPH), a psychostimulant, and atomoxetine (ATX), a select

136 mining the effects of 40 mg methylphenidate (MPH) administration.

137 se in the concurrent use of methylphenidate (MPH) and fluoxetine (FLX) in pediatric populations.

138 ognition-impairing doses of methylphenidate (MPH) on the spiking activity of dorsomedial PFC (dmPFC)

139 The effects of methylphenidate (MPH), atomoxetine (ATMX), and/or physical exercise (EX)

140 eceived direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100mug), amphetamine (AMPH; 0.25, 1.

141 Here, we focus on methylphenidate (MPH), which binds to the dopamine transporter (DAT) and

142 r challenge with 60 mg oral methylphenidate (MPH) (to measure DA release) to assess whether it predic

143 is that the psychostimulant methylphenidate (MPH) improves cognitive and social functioning among the

144 ousands of children receive methylphenidate (MPH; Ritalin) for attention deficit/hyperactivity disord

145 it is well established that methylphenidate (MPH) enhances sustained attention, the neural mechanisms

146 We also show that methylphenidate (MPH), which competitively inhibits DA uptake but does no

147 n rodents demonstrates that methylphenidate (MPH; Ritalin) elicits a narrow inverted-U-shaped improve

148 xamined the degree to which methylphenidate (MPH) (Ritalin) acts within distinct frontostriatal subfi

149 gical enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive prob

150 Pharmacotherapy with methylphenidate (MPH) seems to be the first-line treatment of choice in a

151 reversed by treatment with methylphenidate (MPH), suggesting a defect in brain catecholamine homeost

152 Supplementing RE, we tested methylphenidate(MPH), a dopamine agonist that promotes PFC-dependent lea

153 on was correlated with the initial 90-minute MPH-mediated FC changes.

154 In contrast to the SHRs, neither MPH nor ATMX affected orienting or social behavior in Wi

155 However, neither ATO nor MPH significantly altered impulsive behavior when infuse

156 llin-1 is required for AMPH-induced, but not MPH-induced, hyperlocomotion.

157 The differential action of MPH across regions disappeared at higher concentrations.

158 mine transporter (DAT1), a site of action of MPH, could influence the effects of MPH or ATX on SICI.

159 tial mechanisms of the therapeutic action of MPH.

160 associated with the procognitive actions of MPH across working memory and sustained attention tasks.

161 le of the PFC in the procognitive actions of MPH and demonstrate the divergent dose sensitivity acros

162 ose sensitivity to the beneficial actions of MPH.

163 Here we provide an application of MPH landscapes, a statistical tool with theoretical unde

164 washout, the D2/D3 receptor availability of MPH-treated animals did not continue to decline at the s

165 Attention and behavioral benefits of MPH for childhood cancer survivors are maintained across

166 es, the effects of varying concentrations of MPH (0.25, 1.0, and 4.0 muM) on NE and DA efflux were ex

167 Low concentrations of MPH elicited significantly larger increases in extracell

168 the long-term neurochemical consequences of MPH treatment are unknown.

169 ese findings are discussed in the context of MPH effects on the default mode network and the possible

170 Brief discontinuation of MPH treatment is associated with increased motor and ant

171 ecilia reticulata) to a low, chronic dose of MPH and observed that MPH affected the anxiety/explorato

172 microinfusion of vehicle or varying doses of MPH (.03-8.0 mug/500 nL) directly into the dorsomedial P

173 mental exposure to high therapeutic doses of MPH has short-term effects on select neurotransmitters i

174 The effects of varying doses of MPH were examined on performance of rats in two tests of

175 fter oral administration of various doses of MPH.

176 mental area (VTA) to determine the effect of MPH, FLX, or MPH + FLX on the extracellular signal-regul

177 ors contributed to the beneficial effects of MPH across both cognitive tasks.

178 Finally, there were no effects of MPH administration on any reported measure.

179 Here we investigated the effects of MPH in thalamic connectivity since the thalamus modulate

180 found no relationship between the effects of MPH on impulsivity and D2/3 receptor availability in any

181 support the potentially important effects of MPH on various aspects of cognition known to be associat

182 ction of MPH, could influence the effects of MPH or ATX on SICI.

183 nvestigated the transgenerational effects of MPH through the paternal line.

184 The computational efficiency of MPH primarily stems from two key factors: the utilizatio

185 th either a sustained release formulation of MPH or placebo (N=8 per group).

186 vation period, suggesting that the impact of MPH on puberty is not permanent.

187 This study examines the impact of MPH use in DCD procurements on warm ischemia time (WIT)

188 We measured the impact of MPH, compared with placebo, on behavioral and electrocor

189 ed premature responding whereas infusions of MPH in the core, but not the shell, sub-region significa

190 kg (low dose, n = 10), or (iii) 1.5 mg/kg of MPH increased to 12.5 mg/kg (high dose, n = 10) for a to

191 L/kg of vehicle (n = 10), (ii) 0.15 mg/kg of MPH increased to 2.5 mg/kg (low dose, n = 10), or (iii)

192 nd experiment, 20 subjects received 20 mg of MPH, while 20 matched controls received a placebo.

193 eractivity scores over the first 3 months of MPH medication was correlated with the initial 90-minute

194 ter (DAT) levels and enhances the potency of MPH and amphetamine on dopamine responses and drug-seeki

195 highlight the transgenerational potential of MPH.

196 This work highlights the power of MPH landscapes for quantifying, characterizing, and comp

197 tagenic analysis and the atomic structure of MPH-220-bound skeletal muscle myosin confirmed the mecha

198 indings identify the thalamus as a target of MPH, which increased its metabolism and connectivity.

199 double-blinded, placebo-controlled trial of MPH.

200 Procurements with and without the use of MPH were compared using propensity score matching.

201 olunteers were studied with SPECT on and off MPH.

202 e alpha(1)-antagonist prazosin (.5 mg/kg) on MPH-induced improvement in sustained attention was exami

203 ent on multiple frontostriatal regions, only MPH infusion into the dorsomedial PFC improved task perf

204 VTA) to determine the effect of MPH, FLX, or MPH + FLX on the extracellular signal-regulated protein

205 We administered saline (VEH), MPH, FLX, or MPH + FLX to juvenile Sprague Dawley male rats from post

206 The patients ingested a placebo (lactose) or MPH (0.6 mg/kg; 20 mg maximum) and repeated selected por

207 n 2 d: after ingesting a single dose of oral MPH (20 mg) or placebo (lactose) in a counterbalanced fa

208 -subjects design, participants received oral MPH (20 mg) or placebobefore the retrieval of some of th

209 Results show that oral MPH increased responses to this salient cognitive task i

210 We hypothesized that oral MPH will attenuate ACC hypoactivations and improve assoc

211 s, the transgenerational effects of paternal MPH exposure are unknown.

212 We observed behavioural effects of paternal MPH exposure on offspring and great-grandoffspring that

213 the first study to demonstrate that paternal MPH exposure can affect descendants.

214 0.010; DPH: MD -0.765, P <0.001; mesial PH [MPH]: MD -0.285, P = 0.256).

215 e rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and work

216 using a second-generation multiple-pinhole (MPH) collimator designed for brain SPECT with improved c

217 At PND135, MPH-exposed rats exhibited decreased anxiety in the elev

218 se in boys newly diagnosed with ADHD predict MPH-associated changes in ADHD inattentiveness and hyper

219 To overcome this challenge, we present MPH, a novel software tool designed for efficient genome

220 ans) possessed public health qualifications (MPH, PhD).

221 nitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment

222 with therapeutic doses of sustained release MPH did not have a significant influence on the regulati

223 mulants, including methylphenidate (Ritalin; MPH), cocaine, and amphetamine (AMPH), markedly elevate

224 global rainfall microphysics-based RKE (RKE(MPH)) flux retrieved from radar reflectivity at differen

225 The results suggest that RKE(MPH) flux outperforms the RKE estimates derived from a w

226 Funding assistance for AD's MPH from Scottish Intensive Care Society, Scottish Socie

227 Our main analysis showed a significant MPH-induced FC increase in sensorimotor areas in the fun

228 We tested if a single MPH dose (vs.

229 Previous studies suggest that a single MPH dose modulates resting-state functional connectivity

230 at the brain functional response to a single MPH dose, administered before starting routine treatment

231 imaging (rs-fMRI) under placebo and a single MPH dose, before starting MPH treatment.

232 acebo and a single MPH dose, before starting MPH treatment.

233 In these studies, MPH-induced improvement in sustained attention was aboli

234 Such MPH(2) sources are being used to generate the desired pr

235 The clinical application of such MPH-induced brain-behavior enhancements remains to be te

236 In both humans and animals, systemic MPH improves certain cognitive processes, such as workin

237 When the subjects were not taking MPH, rCBF was higher in the motor, premotor, and the ant

238 ssary for accurate performance in this task, MPH infusion into this region did not affect working mem

239 xploratory decisions than controls, and that MPH would reduce group differences.

240 n mice mimics these effects, confirming that MPH self-administration-induced increases in DAT levels

241 simulated and real datasets demonstrate that MPH achieves comparable accuracy and significantly enhan

242 We found that MPH and ATX had similar effects on SICI.

243 In our exploratory analysis, we found that MPH-induced regional variations in the DAT and NET-enric

244 We hypothesized that MPH would increase thalamic connectivity and metabolism,

245 Our findings indicate that MPH administration, beginning before puberty, and which

246 lower for the placebo and MPH measures, that MPH-induced increases in thalamic metabolism were blunte

247 a low, chronic dose of MPH and observed that MPH affected the anxiety/exploratory behaviour of males,

248 Here we show that MPH self-administration in rats increases dopamine trans

249 resonance imaging (fMRI) studies showed that MPH altered cortico-striatal resting functional connecti

250 Our results showed that MPH at all doses increased Bax in the cortex; the Bcl-2

251 These results, showing that MPH-induced changes in DA levels in the hCd predict rest

252 In conclusion, our results suggest that MPH influences plasticity in the brain of young and adul

253 Our findings suggest that MPH treatment modulates motor and anterior cingulate cor

254 It has been suggested that MPH could cause transgenerational effects because MPH ca

255 system and behavior, and also suggests that MPH administration may not have long-term consequences.

256 This work suggests that MPH, acting via noradrenergic mechanisms, can substantia

257 The MPH software is available at

258 IT (24.0 min vs. 24.0 min, p = .89), but the MPH group demonstrated shorter median operative WIT (cir

259 For the MPH group, repeated measures analysis of variance reveal

260 Eligibility criteria for the MPH trial included an estimated intelligence quotient gr

261 A trend for greater improvement in the MPH group on a measure of verbal memory failed to reach

262 premedication baseline and at the end of the MPH trial while on medication.

263 ERK2 activity within the VTA, we rescued the MPH and FLX-induced behavioral deficits seen in the forc

264 ebo group, the 15 patients randomized to the MPH group had a significantly greater improvement on the

265 owever, alpha1 receptors only contributed to MPH-induced improvement in sustained attention.

266 neurobiological consequences of exposure to MPH at high, abused doses are not well defined.

267 Here we show in rats that exposure to MPH during pre-adolescence causes behavioral and neurobi

268 lternatively, our findings may be related to MPH withdrawal.

269 s found for the SLC6A3 40 bp and response to MPH with only two studies selected.

270 sequences of combined MPH and FLX treatment (MPH + FLX) during juvenile periods are unknown.

271 be pathologies; however, in clinical trials, MPH did not improve treatment outcome in cocaine addicti

272 We administered saline (VEH), MPH, FLX, or MPH + FLX to juvenile Sprague Dawley male r

273 ons in the core and shell, or increased when MPH was infused into either the core and shell sub-regio

274 hite matter (WM).PurposeTo determine whether MPH modulates WM microstructure in an age-dependent fash

275 It was not possible to resolve whether MPH delayed the initiation of the onset of puberty or re

276 t increase in the parietal P3 amplitude with MPH, indicative of enhanced perceptual evidence accumula

277 cerebellum there was an increase of Bax with MPH at all doses, however, there was a reduction of Bcl-

278 ime, chronic modulation of young brains with MPH may exert effects on brain neurochemistry that modif

279 n of Bcl-2, caspase-3, and cytochrome c with MPH (2 and 10mg/kg); in the striatum the treatment with

280 ats showed major structural differences with MPH exposure.

281 hrome c were reduced in the hippocampus with MPH (10mg/kg).

282 red to placebo, significant improvement with MPH was reported by teachers and parents on the Conners'

283 the Bcl-2 and caspase-3 were increased with MPH (1mg/kg) and were reduced with MPH (2 and 10mg/kg);

284 nt in children, male rats were injected with MPH (5 mg/kg) or vehicle twice daily from postnatal day

285 ased with MPH (1mg/kg) and were reduced with MPH (2 and 10mg/kg); the cytochrome c was reduced in the

286 onclusion: The triple-head SPECT system with MPH collimators allows reliable DAT SPECT after administ

287 st mode with a triple-head SPECT system with MPH collimators and a 30-min net scan duration after inj

288 In contrast, subjects treated with MPH gambled at a consistent rate, well above chance, acr

289 (PD90) Sprague Dawley rats were treated with MPH or saline.

290 Treatment with MPH (0.125 mg/kg), ATMX (0.125 mg/kg), or EX (3 weeks of

291 10mg/kg); in the striatum the treatment with MPH (10mg/kg) decreased caspase-3 and cytochrome c; trea

292 d caspase-3 and cytochrome c; treatment with MPH (2 and 10mg/kg) increased Bax and decreased Bcl-2 in

293 s reduced in the cortex after treatment with MPH at all doses; in the cerebellum there was an increas

294 o, we investigated if chronic treatment with MPH at doses of 1, 2 and 10mg/kg could alter the levels

295 Treatment with MPH can at least temporarily reduce some attentional and

296 Juvenile treatment with MPH may result in long-lasting, potentially permanent, c

297 ia were randomized to undergo treatment with MPH or placebo for 16 weeks.